A5041297657- Occupational and environmental lung diseases
- Lung Cancer Treatments and Mutations
- Medical Imaging and Pathology Studies
- Cancer Research and Treatments
- Tissue Engineering and Regenerative Medicine
- Cancer Genomics and Diagnostics
- Lung Cancer Research Studies
- Lung Cancer Diagnosis and Treatment
- SARS-CoV-2 and COVID-19 Research
- Cancer Immunotherapy and Biomarkers
- COVID-19 and healthcare impacts
- RNA modifications and cancer
- Pleural and Pulmonary Diseases
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- COVID-19 Clinical Research Studies
- Neuroendocrine Tumor Research Advances
- Radiopharmaceutical Chemistry and Applications
- Gastric Cancer Management and Outcomes
- Hepatitis B Virus Studies
- Head and Neck Cancer Studies
- Colorectal Cancer Treatments and Studies
- Sarcoma Diagnosis and Treatment
- Mycobacterium research and diagnosis
- Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
University Clinic of Pulmonary and Allergic Diseases Golnik
2016-2025
University of Ljubljana
2024
Splošna Bolnišnica Celje
2017
Introduction: Rearranged during transfection (RET) gene fusions are rare genetic drivers in non-small cell lung cancer (NSCLC). Selective RET-inhibitors such as selpercatinib have shown therapeutic activity early clinical trials; however, their efficacy the real-world setting is unknown. Methods: A retrospective and safety analysis was performed on data from RET fusion-positive NSCLC patients who participated a access program (named patient protocol) between August 2019 January 2021....
Patients with non-small cell lung cancer (NSCLC) presenting mesenchymal-epithelial transition (MET) exon 14 skipping mutation have an unfavorable prognosis standard treatments. Capmatinib is a selective MET inhibitor, which showed promising efficacy in this patient population early trials.We performed retrospective, international, multicenter and safety analysis patients NSCLC treated capmatinib access program between March 2019 December 2021.Data from 81 advanced mutated first- or...
EGFR exon 20 (EGFR Ex20) insertion mutations in non-small cell lung cancer (NSCLC) are insensitive to traditional tyrosine kinase inhibitors (TKIs). Mobocertinib is the only approved TKI specifically designed target Ex20. We performed an international, real-world safety and efficacy analysis on patients with Ex20-positive NSCLC enrolled a mobocertinib early access program. explored mechanisms of resistance by analyzing postprogression biopsies, as well cross-resistance amivantamab. Data from...
Background: Chemoimmunotherapy (CT/IO) with immune checkpoint inhibitors has recently become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). Given uncertain role consolidation thoracic radiotherapy (cTRT) in this setting, we conducted a real-world study to evaluate efficacy and safety cTRT ES-SCLC patients receiving first-line CT/IO. Methods: We performed retrospective analysis treated CT/IO Slovenia from December 2019 June 2024. Patient characteristics, treatment...
Human malignant pleural mesothelioma (MPM) is characterized by dismal prognosis. Consequently, dissection of molecular mechanisms driving malignancy key importance. Here we investigate whether activating mutations in the telomerase reverse transcriptase (
Chemoimmunotherapy (CT/IO) with immune checkpoint inhibitors has recently become the standard of care for extensive-stage small cell lung cancer (ES-SCLC). Given uncertain role consolidation thoracic radiotherapy (cTRT) in this setting, we conducted a real-world study to evaluate efficacy and safety cTRT ES-SCLC patients receiving first-line CT/IO. We performed retrospective analysis treated CT/IO Slovenia from December 2019 June 2024. Patient characteristics, treatment patterns, survival...
Background: Programmed cell death 1/programmed ligand 1 (PD-1/PD-L1) immune-checkpoint blockade is a promising new therapeutic strategy in cancer. However, expression patterns and prognostic significance of PD-L1 PD-1 are still controversial human malignant pleural mesothelioma (MPM).Methods: Formalin-fixed paraffin-embedded (FFPE) tumor samples from 203 MPM patients receiving standard treatment without immunotherapy were collected 5 European centers. cells (TCs) tumor-infiltrating...
The standard first-line systemic treatment for patients with non-oncogene addicted advanced nonsquamous non-small cell lung cancer (NSCLC) is immunotherapy immune checkpoint inhibitors (ICI) and/or chemotherapy (ChT). Therapy after failing ICI +/- ChT remains an open question, and docetaxel plus nintedanib represent a valid second line option.A multicenter retrospective trial of real-life patterns outcomes adenocarcinoma treated the failure was performed. Patients from 2 Slovenian 1 Croatian...
Malignant pleural mesothelioma (MPM) is a devastating malignancy with limited therapeutic options. Fibroblast growth factor receptors (FGFR) and their ligands were shown to contribute MPM aggressiveness it was suggested that subgroups of patients could benefit from FGFR-targeted inhibitors. In the current investigation, we determined expression all four FGFRs (FGFR1-FGFR4) by immunohistochemistry in tissue samples 94 patients. From 13 these patients, able establish stable cell lines, which...
Background: SARS-CoV-2 vaccination in cancer patients is crucial to prevent severe COVID-19 disease course. Methods: This study assessed immunogenicity of on active treatment receiving mRNA-based vaccine by detection anti-SARS-CoV-2 S1 IgG antibodies serum, before, after the first and second doses 3 months a complete primary course vaccination. Results were compared with healthy controls. Results: Of 112 patients, seroconversion rate was 96%. A significant reduction antibody levels observed...
The recommended booster third dose of vaccination against COVID-19 in cancer patients seems reasonable to protect them a severe disease course. A prospective study was designed assess the immunogenicity, efficacy, and safety this cohort. Patients with solid malignancies on active treatment were followed up after primary course their anti-SARS-CoV-2 S1 IgG levels, efficacy case SARS-CoV-2 infection, safety. Out 125 receiving vaccination, 66 received mRNA vaccine, 20-fold increase median...
Due to the devastating COVID-19 pandemic, a preventive tool in form of vaccination was introduced. Thoracic cancer patients had one highest rates morbidity and mortality due disease, but lack data about safety effectiveness vaccines this population triggered studies like ours explore these parameters population. Out 98 with thoracic malignancies vaccinated per protocol, 60–75% experienced some adverse events (AE) after their first or second vaccination, most them were mild did not interfere...
Download This Paper Open PDF in Browser Add to My Library Share: Permalink Using these links will ensure access this page indefinitely Copy URL DOI
Background The relationship between anti-SARS-CoV-2 humoral immune response, pathogenic inflammation, lymphocytes and fatal COVID-19 is poorly understood. Methods A longitudinal prospective cohort of hospitalised patients with (n=254) was followed up to 35 days after admission (median, 8 days). We measured early S1 antibody IgG levels dynamic (698 samples) quantitative circulating T-, B- natural killer lymphocyte subsets serum interleukin-6 (IL-6) response. used machine learning identify...
Background The benefits of chemotherapy in advanced lung cancer patients are well known. However, after evaluating patient eligibility, not all proposed for by multidisciplinary tumour board (MTB) actually receive it. In routine clinical practice, it is important to review the impact this decision on survival and hospital registry serve function perfectly. Thus, aim study was evaluate overall (OS) according delivery initial between January 2010 December 2013 at a single institution.
Background The use of epidermal growth factor receptor (EGFR) TKIs in EGFR-mutated non-small cell lung cancer (NSCLC) moved the survival boundary for these patients up to impressive 19 35 months, as reported seven randomized clinical trials (RCTs). In addition, latest results RCTs show significantly different outcomes with exon deletion and L858R mutation. To find out whether efficacy EGFR is comparable routine practice, overall (mOS) analysis consecutive advanced routinely treated from...
Background It is well known that patients with advanced non-squamous non-small cell lung cancer (NSCLC) benefit substantially from platinum-based chemotherapy containing pemetrexed (pem/platinum ChT). Additionally, maintenance therapy further improves survival in clinical (CB) to induction Cht. Evidence based data show using pem instead of gemcitabine and approach rates pts NSCLC around 13 months (mo). The aim our observational study was evaluate the efficacy first line pem/platinum treated...
<p>Supplementary Figure S6. Relation between TERT mRNA expression and MPM patient survival in the TCGA dataset.</p>